Latest Breaking News On - British columbia registered - Page 9 : vimarsana.com

Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans

Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T [...]

BioVaxys Closes Final Tranche Of Non-Brokered Private Placement

CSE: BIOV, FRA:5LB,OTCQB:BVAXF) ("BioVaxys" or the " Company") is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement (the " Private Placement"). Final Tranche") of the Private Placement, the Company issued 5,349,455 units (" Units") at a price of $0.22 per Unit for total gross proceeds of approximately $1,176,880. Including the first tranche of the Private Placement which completed on July 14, 2021, the Company raised total aggregate gross proceeds of $2,015,555. Each Unit is comprised of one common share in the capital of the Company (a " Common Share") and one whole Common Share purchase warrant (a "

FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH

BioVaxys Closes First Tranche Of Non-brokered Private Placement

CSE: BIOV, FRA:5LB,OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has closed the first tranche ("Tranche 1") of its previously announced non-brokered private placement (the "Private Placement"). Pursuant to Tranche 1 of the Private Placement, the Company has issued 3,812,159 units ("Units") at a price of $0.22 per Unit for gross proceeds of $838,675. Each Unit consists of one common share (a "Common Share") and one whole Common Share purchase warrant (a "Warrant"). Each Warrant is exercisable for one additional Common Share at an exercise price of $0.50 for a period of 30 months. The aggregate Private Placement consists of the sale of up to 9,090,909 Units for total gross proceeds of up to approximately $2,000,000. Closing of the second tranche of the Private Placement is anticipated to complete within the next week.

BioVaxys Announces Non-Brokered Private Placement

Share this article Share this article VANCOUVER, BC, June 28, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB,OTCQB:BVAXF) ("BioVaxys" or the "Company") is pleased to announce a non-brokered private placement (the "Private Placement") consisting of up to 9,090,909 units ("Units") at a price of $0.22 per Unit for total gross proceeds of up to approximately $2,000,000. Each Unit consists of one common share (a "Common Share") and one whole Common Share purchase warrant (a "Warrant"). Each Warrant is exercisable for one additional Common Share at an exercise price of $0.50 for a period of 30 months. All securities issued pursuant to the Private Placement are subject to a statutory hold period of four months and one day from the date of issuance. The Company may pay cash finder's fees on all or a portion of the Private Placement.

BioVaxys Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical Development

BioVaxys And Bioproduction Partner Bio Elpida Begin Construction Of GMP Facility To Produce Clinical Supply For Planned Ovarian Cancer Vaccine Study

/PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (US OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that its bioproduction...

Biovaxys Strengthens Internal Expertise With Appointment Of Scientific Advisor For Ovarian Cancer Vaccine Clinical Program And Papilocare Marketing

/PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, US OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that Charles J. Dunton,...

Biovaxys Strengthens Internal Expertise With Appointment Of Scientific Advisor For Ovarian Cancer Vaccine Clinical Program And Papilocare Marketing